IFNA1 and allergic asthma: In a fundamental and refined study about paediatric patients, targeted short-term treatments with omalizumab, an anti-IgE recombinant humanized monoclonal antibody for the treatment of severe allergic asthma, improved IFN-α responses to HRV.